Production and characterization of monoclonal antibodies specific for 3-amino-2-oxazolidinone Ratthaphol Charlermroj1, Songchan Puthong2, Kittinan Komolpis2, Tanapat Palaga3 1Biotechnology Program, Faculty of Science, 2Institue of Biotechnology and Genetic Engineering, 3Department of Microbiology, Faculty of Science, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330 Abstract 3-Amino-2-oxazolidinone (AOZ) is a tissue bound toxic metabolite derived from the nitrofuran antibiotic, furazolidone. In this study, monoclonal antibodies (MAbs) were generated to specifically detect AOZ, without the process of derivatisation with o-nitrobenzaldehyde. Derivatised form of AOZ, 3-{[(3-carboxyphenyl)-methylene]amino-2- oxazolidinone(CPAOZ) was used as the immunizing hapten for the production of MAbs against AOZ. Hybridomas were generated by fusion of murine myeloma cells (NS1 cells) and splenocytes from BALB/c mice, immunized with CPAOZ-ethylenediamine-bovine serum albumin (CPAOZ-ed-BSA). The antibody produced from hybridoma clone CPAOZ#12 MAb was characterized in terms of cross-reactivity by competitive enzyme-linked immunosorbent assay (ELISA). The result suggested that CPAOZ#12 MAb was highly specific for CPAOZ, 3-{[(2-nitrophenyl)methylene] amino}-2-oxazolidinone (NPAOZ), AOZ and furazolidone. It did not exhibit crossreactivity with various nitrofuran metabolites and other antibiotics. Isotype of CPAOZ#12 MAb was determined by indirect ELISA to be IgG1 subclass. This is the first report of monoclonal antibodies for a specific detection of a nitrofuran metabolite(AOZ) without derivatisation. This monoclonal antibody could be developed into an immunoassay-based test kit for AOZ residue in food. Introduction Results and Discussion Nitrofuran, furazolidone is an antibiotic which has been widely used in the form Preparation of CPAOZ conjugate of food additives for treatment and prevention of gastrointestinal infections caused by Escherichia coli and Salmonella spp. in cattle, pig, poultry and fish. It has also been used as a growth stimulator. However, the European Union (EU) does not assign a maximum residue limit for furazolidone because of the potential carcinogenic effects Fig.1 TLC analysis of CPAOZ synthesis (a) of its residues on human health[1]. Monitoring of furazolidone has not been effective visualized by ninhydrin stain,(b) visualized by UV light; lane 1: 3-carboxybenzaldehyde, 2: (3-amino- in the past due to the instability and rapid metabolism of the drug. However the 2-oxazolidinone), 3: pyridine, 4: sample before metabolite, 3-amino-2-oxazolidinone (AOZ), is more stable in vivo and in vitro which is reflux, 5: sample after reflux, 6: sample after flow of nitrogen gas. Elution solvent : 5% methanol in released upon mild acid hydrolysis [2-3]. Various methods have been published for chloroform the determination of AOZ by HPLC-UV[2,4-5], LC-MS[6] and LC-MS/MS[7]. Nevertheless, there is now an urgent need for rapid, high capacity screening methods for the detection of AOZ residue. Currently, there are immunoassay-base screening tests capable of detecting AOZ. The sample, however, must be derivatized with o- nitrobenzaldehyde to form 3[[(2-nitrophenyl)-methylene]-amino]-2- oxazolidinone(NPAOZ) [8,9]. In this study, monoclonal antibodies for specific Fig.2 Molecular weight detection of nitrofuran metabolite(AOZ) were produced. They could be developed into analysis by MALDI- TOF/MS (a) cBSA, (b) an immunoassay-based test kit for detecting AOZ residue in food without sample CPAOZ-ed-BSA and derivatization. (c) CPAOZ-OVA Materials and Methods Preparation of CPAOZ conjugate CPAOZ has Rf approximately 0.03 by TLC analysis. Molar ratio of hapten to carrier proteins after conjugation was calculated to be 14.5:1 for CPAOZ:cBSA and 1:1 for CPAOZ:OVA. (3-amino-2- (3-carboxy Characterization of MAbs oxazolidinone) benz aldehyde) (ethylenediamine-BSA) IC50 = 74.530 ng/ml IC50 = 1,042 ng/ml Competitiors LOD = 9.616 ng/ml reactivity(%) LOD = 11.324 ng/ml LOQ = 31.733 ng/ml LOQ = 37.369 ng/ml <0.01 <0.01 <0.01 (3-{[3-carboxyphenyl) <0.01 methylene]amino}-2- CPAOZ (ug/ml) <0.01 oxazolidinone)) NPAOZ (ug/ml) <0.01 CPAOZ-ed-BSA CPAOZ-OVA IC50 = 15.39 ug/ml IC50 = 2.832 ng/ml <0.01 (used for immunization) (used for ELISA) LOD = 0.501 ug/ml LOD = 0.251 ng/ml Flumequine <0.01 LOQ = 1.654 ug/ml LOQ = 0.827 ng/ml Norfloxacin <0.01 MALDI-TOF/MS MALDI-TOF/MS Penicilin G <0.01 Clenbuterol <0.01 Salbutamol <0.01 Production of monoclonal antibodies (MAbs) Furazolidone (ug/ml) AOZ (ug/ml) Chloramphenicol <0.01 Inject CPAOZ-ed-BSA, Oxytetracycline <0.01 50 ug/mices, Fig.3 Inhibition curves of competitive ELISA showing the ability of CPAOZ#12 MAbs to react with (a) CPAOZ, (b) NPOAZ, (c) Furazolidinone Boost every 2weeks and (d) AOZ Isotype of CPAOZ#12 MAb was determined by indirect ELISA to be IgG1 subclass. Sensitivity (IC50) of CPAOZ#12 MAb to CPAOZ, NPAOZ, furazolidinone Highest Ab titre and AOZ are 74.530 1,042 2.832 and 15,390 ng/ml, respectively. Sacrifice References Female BALB/c Myeloma cells 1. J.E.M. Van Koten-Vermeulen, M.F.A. Wouters, F.X.R. Van Leeuwen, Report of the 40th mice, 6-8 weeks (NSI cells) Meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), (polyethyleneglycol) World Health Organisation, Geneva, 1993, p.85 2. A. Conneely. et al., Analyst., 2002, 127, 705-709 3. R.J. McCracken. et al., Food Addit. Contam., 1997, 287 positive Subclone Screen by 4. A. Conneely. et al., Anal. Chim. Acta., 2003, 483, 91 until monoclone indirect ELISA 5. L.A.P. Hoogenboom. et al., Food Addit. Contam., 1992, 623 6. R.J. McCracken. et al., J. Chromatogr. B.,1997,691, 87 Hybridoma cells in 7. A. Leitner. et al., J. Chromatogr. A., 2001,939, 49 HAT medium 8. Kevin M. Cooper. et al., Analytica Chimica Acta.,2004, 520,79–86 Characterization
• isotype by isotyping test kit 9. M. VASS. et al., Vet. Med. , 2005,50(7), 300–310
• sensitivity and cross-reactivity by competitive ELISA Acknowledgment This research is partially funded by graduate research fund, Chulalongkorn University
«Er steht halt jeder Zeit»: Junge Männer greifen zu Viagra Von Katrin Hafner. Aktualisiert am 22.04.2009 In der Schweiz werden immer mehr Potenzmittel konsumiert. Interessiert daran sind auch junge Männer – aus Neugierde, Unwissenheit oder weil sie unter Leistungsdruck stehen. Der 16-Jährige äusserte seinen Wunsch direkt: Er möchte gerne Viagra verschrieben bekommen, da
Chronic Daily Cannabis Smoking: Neuroadaptation, Residual Cannabinoid Excretion & Psychomotor Impairment Professor Dr. Dr. (h.c.) Marilyn A. Huestis Chief, Chemistry and Drug Metabolism Section, Intramural Research Program National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore USA, and Adjunct Professor, School of Medicine, University of Maryland